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Luca Serrn-Aguilera,[a] Roberto Nuti,[b] Luisa C. Lpez-Cara,[a] Miguel . Gallo Mezo,[a] Antonio Macchiarulo,*[b]
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1 Introduction
Choline kinase (CK) is a homodimeric enzyme that catalyses
the transfer of the g-phosphate group from ATP to choline
rendering ADP and phosphocholine (PCho), and it is the
first committed step in the Kennedy pathway leading to
the synthesis of phosphatidylcholine (PtdCho).[1] PtdCho is
a crucial phospholipid in membrane neogenesis for suc-
cessful growth and proliferation in human cells, and in
other eukaryotic and bacterial pathogens.[2a–c] In humans,
there are three isoforms of CK being the a-isoforms
(HsCKa1 and HsCKa2) validated drug targets in cancer dis-
ease.[3]
Initially the first inhibitor for HsCKa1 was Hemicholinium-
3 (HC-3, 1),[4] though this compound showed multiple life-
threatening side effects.[5] To ameliorate the toxicity and
keep key HsCKa-binding features of HC-3, a large number
of generally large symmetrical or asymmetrical biscationic
compounds based on HC-3 structure were synthesized
along the last years (Figure 1).[6a–e] One of these molecules,
TCD-717 (2), has even passed Phase I under clinical trials
for advanced solid tumors.[7] Very recently the first crystal
structures of several complexes of HsCKa1 bound to some
of these inhibitors have enlightened their binding mode
majorly through interactions to the choline-binding site.[8a–c]
Inhibitors have been also developed using not only a ration-
al approach but also virtual and high-throughput screening
of small-molecule libraries.[9]
Despite the extensive information on CK inhibitors, there
is not a study dissecting the key chemical features shared
among the large number of inhibitors that are important
for enzyme recognition. Herein, we propose a pharmaco-
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Abstract : Choline kinase (CK) catalyses the transfer of the
ATP g-phosphate to choline to generate phosphocholine
and ADP in the presence of magnesium leading to the syn-
thesis of phosphatidylcholine. Of the three isoforms of CK
described in humans, only the a isoforms (HsCKa) are
strongly associated with cancer and have been validated as
drug targets to treat this disease. Over the years, a large
number of Hemicholinium-3 (HC-3)-based HsCKa biscation-
ic inhibitors have been developed though the relevant
common features important for the biological function
have not been defined. Here, selecting a large number of
previous HC-3-based inhibitors, we discover through com-
putational studies a pharmacophore model formed by five
moieties that are included in the 1-benzyl-4-(N-methylanili-
ne)pyridinium fragment. Using a pharmacophore-guided
virtual screening, we then identified 6 molecules that
showed binding affinities in the low mM range to HsCKa1.
Finally, protein crystallization studies suggested that one of
these molecules is bound to the choline and ATP-binding
sites. In conclusion, we have developed a pharmacophore
model that not only allowed us to dissect the structural im-
portant features of the previous HC-3 derivatives, but also
enabled the identification of novel chemical tools with
good ligand efficiencies to investigate the biological func-
tions of HsCKa1.
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phore model formed by 5 structural features, and validate
it by the discovery of new simpler molecules against
HsCKa1 using a virtual screening approach. Not only we
discover efficient molecules that bind to HsCKa1 in the low
mM range but we also describe the binding mode for one
of these molecules. Therefore, this thorough study serves
to understand the common moieties of hundreds of com-
pounds essential for CK recognition and in turn to design
and discover new efficient and simpler molecules that
might have potential applications as lead molecules to de-
velop new anticancer agents.
2 Methodology
2.1 Pharmacophore Model Design
2.1.1 First Docking Study
The initial docking study of 83 inhibitors chemically derived
from HC-3 (Figure S1) into HsCKa1 was developed after
protein and ligands preparation using different utilities in-
cluded into Maestro 9.3.[10] The crystal structure of HsCKa1
complexed with HC-3 was downloaded from the Protein
Data Bank (PDB ID: 3G15). After waters and metal ions de-
letion, chain A was submitted to Protein Preparation
Wizard[12] in order to add hydrogens, assign correct bond
orders, convert selenomethionines into methionines and
solve sterical conflicts. Hydrogens were minimized at phys-
iological pH, whereas heavy atoms minimization was car-
ried out with Impact[12b] Refinement module using OPLS-
2005 force field and terminated when root-mean-square
deviation (RMSD) reached a maximum cutoff of 0.3 . ADP
and HC-3 states at physiological pH were also generated
with Protein Preparation Wizard. A formal charge of 2 for
ADP and of +2 for HC-3 was selected. The set of 83 HC-3
derivatives was downloaded from the Binding Database[13]
in SD format and pre-processed with LigPrep 2.5 in order
to add hydrogens, remove counterions, generate ionization
states at physiological pH with Epik,[12a] generate low-
energy ring conformations and optimize their geometries
by OPLS-2005. In this set of compounds there were active
and inactive molecules with a value of IC50 ranged from
0.4 mM to higher than 100 mM. SP flexible docking study
was performed with Glide[14] 5.8 based on a receptor grid
of 10  length centered on HC-3.
2.1.2 HC-3 Pharmacophoric Hypothesis (Hypothesis-1).
An XP precision refinement of HC-3 pose into the PDB
entry 3G15 was developed with Glide 5.8 before generating
a pharmacophoric hypothesis for HC-3 with E-pharmaco-
phore.[15] This hypothesis (hypothesis-1) included 6 features
that were used as input by Phase[16] 3.4 together with 5 
of excluded volume and a feature-matching tolerance crite-
ria defined by at least 3 out of 6 pharmacophoric features
located at a maximum distance of 2.0 .
Specifically, the excluded volume is the space occupied
by residues of the binding pocket lying in a sphere of 5 
from HC-3 that cannot be occupied by any moiety of a po-
tential hit compound due to the formation of steric bumps.
The feature-matching tolerance is the minimum number
and relative distances of pharmacophoric features that
a compound should fit to be considered a potential hit
molecule.
The training set was composed of 83 preprocessed com-
pounds and the excluded volume was centred on the HC-3
of the PDB entry 3G15 (Figure S2 Supporting Information).
A number of 100 conformers was generated per rotatable
bond with a maximum of 1000 conformers per structure
using ConfGen.[17] Training set compounds were firstly
ranked according to the number of matched pharmaco-
phoric features (descending order from 6 to 3), and then to
the Fitness score. Specifically, the Fitness score is a parame-
ter measuring the goodness of the fit of the compound on
the pharmacophoric features, with higher values meaning
better fitting of the pharmacophore model.
2.1.3 1-Benzyl-4-(N-methylaniline)pyridinium Pharmacophore
Hypothesis (Hypothesis 2)
This alternative pharmacophore searching was based on
the 1-benzyl-4-(N-methylaniline)pyridinium fragment. This
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Figure 1. Chemical structure of compounds HC-3 (1), TCD-717 (2) and CHEMBL-364022 (3).
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fragment was optimized and energy minimized with Lig-
Prep 2.5. Then, it was rigidly docked into the PDB entry
3G15, using a grid of 10  centered on HC-3 and the Stan-
dard Precision protocol (SP). The binding pose where its
benzylic ring was overlaid with one of the phenyls of HC-3
(Figure S3 Supporting Information) was submitted to an XP
refinement before the search of the pharmacophoric fea-
tures with E-pharmacophore. Manual definition of the phar-
macophoric features was made including the positive
charge, the amino nitrogen or the hydrophobic moiety
(bound to this amino nitrogen). The pharmacophoric fea-
tures defined by E-pharmacophore were used as input in
Phase 3.4 calculations together with an excluded volume of
5  from the 1-benzyl-4-(N-methylaniline)pyridinium frag-
ment, as defined previously. A pool of twelve pharmaco-
phoric hypotheses was thus generated. The feature-match-
ing tolerance was defined by 3 out of the 6 pharmacophor-
ic features located at a maximum distance of 2.0 . In this
case, 11 active molecules (IC50<1.5 mM) and 11 inactive
compounds (IC50>100 mM) of the initial 83 molecules were
selected to define the test set (Table S1 Supporting Infor-
mation) and their conformer generation was made as previ-
ously described. In particular, this reduction of the dataset
from 83 molecules to 22 compounds was done in order to
obtain a clear and balanced separation between active and
inactive compounds. The best hypothesis (hypothesis-2)
among the twelve ones was selected according to its ability
to select not only the minimum number of inactive com-
pounds but also to rank at first positions the active ligands
and to show a correlated trend between the IC50 values
and the Fitness scores of ligands (Table S2 Supporting Infor-
mation).
2.2 Pharmacophore Based Virtual Screening
All the compounds included into Enamine,[18] Chem-
bridge[19] and Life Chemicals[20] libraries were preprocessed
with LigPrep 2.5 and ConfGen in order to add hydrogens,
remove counterions, generate ionization states at physio-
logical pH, generate low-energy ring conformations, opti-
mize their geometries and generate conformers. In particu-
lar, a maximum number of 100 conformations were gener-
ated for each molecule in an energy window of 10 kcal/mol
from the relative global minimum. Phase 3.4 was used for
the searching and the number of minimum matches that
the finally selected compounds should share with the hy-
pothesis-2 was set to 3 pharmacophoric features out of the
5 (Figure S4 Supporting Information). Each screening was
launched separately indicating 5000 as maximum number
of hits. As a result of the screening of the three libraries,
a total of 8621 molecules was selected. As criteria for filter-
ing only those hits that could show a better affinity for
HsCKa1, ligands showing a Fitness score better than the
most active compound in the test set according to hypoth-
esis-2 (Fitness>0.366) were taken into account. After this
selection, 72 compounds were docked with Glide SP into
the choline-binding site of HsCKa1 using a grid of 10 
centered on the HC-3. After this, Prime[12c] MM-GBSA rescor-
ing calculations were performed using the default parame-
ter set to compute the binding energies of the 72 hits.
Among the 20 hits showing Prime MM-GBSA binding
scores lower than 36.79 kcal/mol, 11 compounds were se-
lected according to their commercial availability and prices
to be tested on the HsCKa1.
2.3 Cloning and Purification of hCK
Details about cloning and purification of human CKa1 and
CKb have been previously reported.[8b]
2.4 Tryptophan Fluorescence
All compounds were prepared in 100% DMSO. Before run-
ning the binding experiments, fluorescence property of the
compounds was evaluated measuring the fluorescence
signal at varying concentrations in a specific buffer (25 mM
Tris, 150 mM NaCl, pH 7.5) containing an equivalent % of
DMSO as the one used for the binding assay. The excitation
wavelength was 280 nm while the emission was between
300–400 nm (typical emission range for protein trypto-
phan). No fluorescence signal was detected for the com-
pounds that could interfere with the binding assay.
The binding affinity constant (Kds) of the compounds
against HsCKa1 and HsCKb, were measured by monitoring
the quenching of tryptophan fluorescence. All experiments
were carried out in a Cary Eclipse spectrofluorometer
(Varian) at 25 8C with the enzymes at 1 mM, and concentra-
tions of compounds varying from 0.1 to 10 mM for HsCKa1
and 0.5 to 200 mM for HsCKb in 25 mM Tris, 150 mM NaCl,
pH 7.5. Fluorescence emission spectra were recorded in the
300–400 nm range with an excitation wavelength of
280 nm, with slit width of 5 nm. Controls were determined
by incubating the enzymes with equivalent amounts of
DMSO. As indicated previously, data analysis was performed
in Prism 6 (GraphPad software)[21] considering a model with
a single binding site (Equation 1), where F0 is the intrinsic
fluorescence of the enzyme in the absence of quencher
(Q), F1 is the observed fluorescence at a given quencher
concentration, fa is the fractional degree of fluorescence,
and Kd is the dissociation constant.
1 F1
F0
¼ fa  Q½ 
Kd þ Q½  ð1Þ
2.5 Protein Crystallography
HsCKa1 at 11.60 mg/ml was preincubated at room temper-
ature with 7.5 mM hit 10 in buffer 25 mM Tris/HCl, 150 mM
NaCl pH 7.5 (DMSO is at 5% final concentration in the mix).
The sitting-drop vapor diffusion method[22] was used to
produce crystals by mixing 0.5 mL of the protein solution
and an equal volume of mother liquor (crystals appeared in
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18% polyethylene glycol (PEG) 5000, 0.2 M calcium acetate,
0.1 M 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
(HEPES) pH 8.5 and 1.0 M guanidine hydrochloride). Ortho-
rhombic crystals (space group P212121) grew within 6–
7 days. The crystals used in this study were cryoprotected
in mother liquor solutions containing 20 % ethylenglycol
and frozen in a nitrogen gas stream cooled to 100 K.
Diffraction data of the binary complexes were collected
at beamline I04–1 (Diamond, Oxford). The data was pro-
cessed and scaled using the XDS package[23] and CCP4 soft-
ware;[24] relevant statistics are given in Table S3 (Supporting
Information).
2.6 Structure Determination and Refinement
The structure of the binary complex was solved by molecu-
lar replacement using PDB entry 3G15 as a template. Initial
phases were further improved by cycles of manual model
building in Coot[25]and refinement with REFMAC5.[26] The
final model was validated with PROCHECK,[27a] model statis-
tics are given in Table S3. Coordinates and structure factors
have been deposited in the Worldwide Protein Data Bank
(wwPDB; see Table S3 Supporting Information for the pdb
code).
3 Results and Discussion
3.1 Computational Studies Suggest a Pharmacophore Model
that is Present in the Fragment 1-Benzyl-4-(N-
methylaniline)pyridinium
A focused library of 83 HC-3 derivatives (Figure S1) regis-
tered in the Binding Database was assembled to carry out
our computational studies. This group of molecules varied
from poor to highly active compounds according to their
IC50 values obtained by studies on cancer cell lines and par-
tially purified CK. Most of the molecules as well as HC-3 (1)
contain a biphenyl-moiety acting like a spacer between
two cationic heads that in turn serve as a criterion to classi-
fy these compounds as symmetrical or asymmetrical (Fig-
ure 2a and Figure S1). The majority of them contain pyri-
dine and quinoline cationic heads with the exception of
two rarely cationic fragments of 3-quinuclidinol and 3-di-
methylamino1-propanol (Figure S1). Specifically, the pyri-
dine derivatives have the aromatic ring covalently bound
to a tertiary nitrogen, leading to a larger delocation of the
electrons (Figure S1). Initially these molecules were docked
into the choline-binding site of HsCKa1 (PDB entry 3G15)
pursuing a structure-based approach. As a result, no differ-
ence was found in the binding modes of the top ranked
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Figure 2. Pharmacophore hypothesis development. a) General chemical structure of the 83 Hemicholinium-3 (HC-3) derivatives that serve
as starting point of the study. b) Docking pose of CHEMBL-364022 (3). c) Comparison of compounds 4–5 : the phenyl ring condensed to
the pyridine does not seem to be essential for the enzyme inhibition. d) Feature combinations (R: ring, P: positive charge, N: nitrogen
atom and H: hydrophobic) for finding the best hypothesis called hypothesis-2 (number #5). e) Pharmacophore model with the signature
PNRRR.
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poses of actives and inactives ligands, and thus no attempt
to rationalize the different inhibitory activities could be
done after this first step.
Consequently, and owing to the non-successful struc-
ture-based strategy, we deemed of interest to undertake
a ligand-based approach using HC-3 to generate a first at-
tempt of pharmacophoric hypothesis (hypothesis-1) com-
posed of excluded volumes and 6 features (RRDDAP, Fig-
ure S2 Supporting Information) as detailed in the method
section. The pharmacophoric hypothesis-1 was challenged
with the objective of differentiating active from inactive
compounds in the focused library of 83 molecules. Again,
only 14 compounds of the library were successfully classi-
fied, with the pharmacophoric hypothesis-1 being in most
cases unable to identify active and inactive compounds on
the basis of the Fitness score. Hence, we next focused on
one of the most active compound in the library, coded
CHEMBL-364022 (3) according to the database of bioactive
drug-like small molecules, and endowed with an IC50 value
of 2.3 mM (Figure 2b). CHEMBL-364022, as suggested by
docking studies, binds to the choline-binding site with its
1-benzyl-4-(N-phenyl)quinolinium moiety, whereas the re-
maining part of the molecule is exposed to the solvent
(Figure 2b). Comparing this fragment to the CHEMBL-
191595 (4) and other compounds of the library such as
CHEMBL-364145 (5), we noticed that the phenyl condensed
to the quinoline moiety should not be important for the in-
hibitory activity, since the IC50 values of these compounds
were in the same range of potency (Figure 2c). For this
reason, the 1-benzyl-4-(N-methylaniline)pyridinium frag-
ment was selected as interesting scaffold for generating
a pool of twelve alternative pharmacophoric hypotheses
(Figure 2d) that included different combinations of the pos-
itive charge of the pyridinium ring (feature P), a hydrogen
bond donor group (feature N), a hydrophobic aliphatic
group (feature H), and three aromatic groups (features R).
The best hypothesis, namely hypothesis-2 (n. #5, Figure 2d),
was the one able to explain the activity of 8 out of 22 com-
pounds (4 actives and 4 inactives compounds, Table S2)
and to show a trend between the Fitness score and the IC50
values of the compounds (Table S2). As shown in Figure 2e,
hypothesis-2 was composed of a positive charge (P), a hy-
drogen bond donor group (N) and three aromatic groups
(RRR).
3.2 A Ligand-Based Virtual Screening on HsCKa1 Provides
New Potential Hits that are Validated by Tryptophan
Fluorescence Studies
The pharmacophoric model based on hypothesis-2 was
used to discover smaller and simpler compounds. To this
end, a virtual screening protocol was carried out using
three filtering steps (Figure 3a). Firstly, the hypothesis-2 en-
riched with excluded volumes derived from the binding
mode of CHEMBL-364022 to HsCKa1 was employed to
screen the Enamine, Chembridge and Life Chemicals virtual
compound libraries (8621 compounds in total). Specifically,
compounds showing Fitness score higher than 0.366 and
compliant to excluded volumes were selected, yielding 72
molecules. In order to further reduce the number of com-
pounds, this set of molecules was next docked into the
binding site of HsCKa1.
The criterion for compound selection in the second fil-
tering step was the Prime MM-GBSA docking score. At this
regard, it should be mentioned that a recent study has re-
ported the improvement resulting from the incorporation
of Prime MM-GBSA scoring function in docking studies.[28]
Accordingly, only the first twenty compounds having MM-
GBSA scores lower than 36.79 kcal/mol were selected for
further evaluations. From the resulting list of 20 com-
pounds, only 11 of them were selected and purchased (Fig-
ure S5) in the third filtering step on the basis of their availa-
bility and pricing quotes.
The final 11 compounds were evaluated on HsCKa1
using tryptophan fluorescence spectroscopy. Of these mol-
ecules, only 6 compounds (hits 6–11) showed binding ac-
tivity to the enzyme, with Kds ranging from 0.44 to 7.9 mM
(Figure 3b and Table 1).
To assess whether these compounds selectively bind to
HsCKa1, we also carried out the same experiments on
HsCKb. A recent manuscript clearly showed that a potent
anti-cancer effect inducing maximum apoptosis was only
achieved when HsCKa expression was specifically dimin-
ished without affecting HsCKb levels.[29] Therefore it is im-
portant to have selective and potent compounds against
HsCKa versus the HsCKb isoform. According to the Kd
values, the compounds are selective on the HsCKa1, being
hits 7 and 9 the most selective of all, respectively (Table 1).
Selectivity has been previously explained by a major flexi-
bility of Trp420 in HsCKa1 compared to a reduced flexibility
of its homologous (Trp353) in HsCKb. This is owed to the
location of a leucine at the back of Trp420 in HsCKa1 in-
stead of a more bulky phenylalanine at the back of Trp353
in HsCKb leading to a less flexible tryptophan.
Another important aspect of these compounds comes
from the analysis of their ligand efficiency (L.E.) values[30]
compared to the ones previously described for the HC-3
derivatives. This feature is defined as the ratio of DG and
the number of non-hydrogen atoms of the molecules. The
majority of the molecules in this study present better L.E.
than previous heavier compounds such as HC-3, compound
12 (PDB ID: 3ZM9)[8c] and compound 13 (PDB ID: 4BR3)[8b]
(Table 1). In particular hit 9 with the best Kd is the second
more efficient molecule with a L.E. of 0.34 whereas hit 10
despite having a moderate Kd, has a L.E. of 0.38, and
therefore it is the more efficient molecule (Table 1). A plau-
sible explanation for the lower L.E. values found in HC-3 de-
rivatives is that a significant fragment of these HC-3 deriva-
tives is exposed to the solvent and consequently does not
show interactions with the enzyme. This is further support-
ed by our docking studies (Figure 2b) and previous crystal
structures in complex with these heavier compounds.[8b]
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3.3 Hit 10 Binds to the Choline and ATP-Binding Sites
Although docking studies clearly suggested that the com-
pounds bound to the choline-binding site (Figure S6 Sup-
porting Information), we further carried out crystallization
experiments with all the positive hits (Figure 3b) to have
more convincing data. Despite of a large number of trials
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Figure 3. a) Hits filtering steps. b) Hits that showed binding to HsCKa1 in the low mM range, and companies from which they are pur-
chased. c) Quenching of intrinsic HsCKa1 tryptophan fluorescence measured at increasing concentrations of hit 9. A black arrow indicates
the decrease of the maximal fluorescence signal with increasing concentrations of the compound.
Table 1. Kd values of the six hits for HsCKa1 and HsCKb. All the hits are 3–160 fold selective on the HsCKa1 over HsCKb. Hit 9 shows the
best binding to the HsCKa1, the greatest selectivity for this isoform and is also one of the compounds with the best ligand efficiency (L.E.).
If the hits are compared with HC-3, most of them show a better value of ligand efficiency.
Hit (Supplier) Kd (mM) HsCKa1
HsCKa1 HsCKb Selectivity L.E. (kcal/(mol atom))
(Kd for CKb)/(Kd for CKa1)
9[19] 0.4380.1 709 160 0.34
8[18] 0.5260.1 36.53.2 69 0.32
10[19] 2.600.7 59.53.7 23 0.38
11[19] 4.141.3 41.37.8 10 0.27
7[19] 7.41.6 230.8 3 0.21
6[18] 7.90.5 68.32.3 9 0.20
HC-3 (1) 0.1800.05 – – 0.26
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we only managed to get the crystal structure of HsCKa1 in
complex with hit 10 at 2.25  (Methods and Table S3). Suc-
cessive iterative model building and refinement cycles were
carried out to produce a final model with good refinement
statistics (R=0.224, Rfree=0.268 for HsCKa1/hit 10, Table S3
Supporting Information). The structure is a dimer in which
each monomer is formed by a small N-terminal and a large
C-terminal. Whereas the ATP binding site is located in
a cleft formed by N- and C-terminal residues, the choline-
binding site is found in a deep hydrophobic pocket. Two
molecules of hit 10 were visualized into the choline and
ATP binding sites of one of the monomers (molecule-1 and
molecule-2. Figure 4a). Conversely, only one molecule was
found in the choline-binding site of the second monomer
(molecule-1, Figure 4a). Molecule-1, which is the one that
occupies a deeper location in the choline-binding site, has
also better defined electron density than molecule-2. Mole-
cule-1 establishes p–p interactions with Trp423 and
Phe435, a cation–p interaction with Trp420 and a hydrogen
bond with Glu349 (Figure 4a) whereas molecule-2 estab-
lishes an electrostatic interaction with Asp330 and a hydro-
gen bond with Asn311 (Figure 4a). Overall, this compound
contains 3 of the 5 moieties present in our proposed phar-
macophore (Figure S4) that in turn are required to interact
with the protein as described above (Figure 2e and 4a).
Owing to these interactions, hit 10 shows two binding
modes that allow on one hand to compete with the mag-
nesium atom (this metal is coordinated by Asp330 and
Asn311 and the phosphate groups) and the ADP phosphate
groups (Figure 4b), and on the other hand to mimic the
positive charge present in HC-3,[31] choline/phosphocholine,
and HC-3 derivatives such as compound 12,[8c] compound
13[8b] and compound 14[8a] (Figures 4b–f). In all these com-
pounds the positive charge is key to maintain a cation-p in-
teraction with Trp420. Compound 1, as well as hit 10, is
also located in the ATP and choline-binding sites and there-
fore both of them act as dual competitive inhibitors of
choline and ATP.
Overall, the results of crystallization studies of HsCKa1 in
complex with hit 10, combined with previous structural
data,[8] contribute to support a scenario in which the major-
ity of HsCKa1 inhibitors generally occupy the choline-bind-
ing site, using only one positive charged moiety of the mol-
ecule to engage aromatic residues in cation-p interactions.
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Figure 4. Crystal structures of HsCKa1 complexes. Close-up views of hit 10 (a), HC-3 and ADP (b, PDB entry 3G15), phosphocholine (c, PDB
ID entry 2CKQ), compound 12 (d, PDB ID entry 3ZM9), compound 13 (e, PDB ID entry 4BR3) and compound 14 (f, PDB ID entry 4CG8)
bound to the HsCKa1 active site, respectively. Hydrogen bonds and electrostatic interactions are represented in green and pink dashes, re-
spectively.
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Although the second positive charge of biscationic com-
pounds is usually exposed to the solvent, for one particular
compound inducing the aperture of an adjacent new bind-
ing site to the choline binding site, it was found that both
positive charges are engaged in cation-p interactions.[8a] Re-
markably, a second copy of hit 10 has been identified in
the ATP binding site, mimicking a magnesium atom that is
coordinated by the ATP g-phosphate and making electro-
static and hydrogen bond interactions with polar residues.
Despite the accuracy in the prediction of the binding
mode of the compounds by docking studies, some devia-
tions were found analyzing a superposition of the docked
pose of hit 10 with the adopted one in the crystal structure
(Figure 5). These deviations are in terms of the number of
molecules of the compound that are present in the binding
site, the bioconformation of the compound, the location of
the positive charge and the rotation of some important res-
idues involved in the binding. More exactly, the docking
studies are not able to predict : a) the entering of two mol-
ecules of hit 10 into the choline-binding pocket (Figure 5a) ;
b) its cis-bioconformation, where the real distance between
the aromatic moieties is 5.242  instead of 8.003  (Fig-
ure 5b); c) the location of the quaternary nitrogen, which in
the crystal structure is 2.971  far from its docking pose
(Figure 5b) and d) the noticeable rotation (more than 408)
that some residues such as Asp330 (Figures 5c) and Trp420
(Figure 5d) adopt in the crystal structure. All these data
provide clues about the current limitations of the docking
programs, which must be taken into account in the inter-
pretation of any theoretical result.
4 Conclusions
CK has an essential role in the biosynthesis of cellular mem-
brane phospholipids and in cell proliferation. In humans,
the a isoform has been proposed as a validated drug
target to treat cancer and consequently along the last
years a large number of HC-3 derivatives acting as inhibi-
tors of HsCKa1 have been discovered. Generally these com-
pounds are large molecules whose common structural fea-
tures, important for their binding mechanism and biologi-
cal activity, have not been elucidated. To dissect the key
features of HC-3 derivatives, we have conducted a computa-
tional study to propose a pharmacophore model formed
by five moieties that are included in the 1-benzyl-4-(N-
methylaniline)pyridinium fragment. Then this pharmaco-
phore model has been used to carry out a virtual screening
of several commercial libraries leading to the finding of six
small monocationic compounds with better ligand efficien-
cies than the previously reported ones. Although docking
studies suggest that these 6 molecules bind to the choline-
binding site, our crystal structure of HsCKa1/hit 10 sug-
gests that this particular molecule has a dual mechanism
and might compete with ATP/Mg+2 and choline. In conclu-
sion, a pharmacophore model is provided to unravel the
key moieties of HC-3 derivatives that probably account for
their biological functions, and to discover new efficient and
simpler HsCKa1 ligands that may represent starting lead
compounds on the way to develop novel anticancer
agents.
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ed compounds to be tested; Fitness score of the test set
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